National Guideline Clearinghouse | Alemtuzumab for treating relapsing–remitting multiple sclerosis.

FULL-TEXT ►

National Guideline Clearinghouse | Alemtuzumab for treating relapsing–remitting multiple sclerosis.



National Institute for Health and Care Excellence (NICE)

Guideline Title

Alemtuzumab for treating relapsing–remitting multiple sclerosis.

Bibliographic Source(s)

National Institute for Health and Care Excellence (NICE). Alemtuzumab for treating relapsing–remitting multiple sclerosis. London (UK): National Institute for Health and Care Excellence (NICE); 2014 May. 58 p. (Technology appraisal guidance; no. 312).

Guideline Status

This is the current release of the guideline.